CDH1 and cancer: Cancer-SIGVAR uses a ClinGen update of ACMG/AMP guidelines (Abou Tayoun et al. 2018), considers ClinGen’s specific guidelines for PTEN (Mester et al. 2018), CDH1 (Lee et al. 2018), RASopathies (Gelb et al. 2018), RUNX1 (Luo et al. 2019) and hearing loss (Oza et al. 2018), and other sources (https://www.acgs.uk.com/media/11285/uk-practice-guidelines-for-variant-classification-2019-v1-0-3.pdf).